Who to Watch Among the Pure Play DX Companies?
- High fliers with cache’ among traders and investors: CPHD,EXAS.
- Value plays for earnings turn-around: ALR, QGEN.
- Niche companies: NEOG, SQNM.
- Personalized medicine plays: GHDX, QGEN.
- M&A potential? Very quiet lately.
- Whale deal for 2012: spin-off of ABT Diagnostic Div.
- Roche hostile bid for ILMN and emerging molecular DX tools like sequencing.
- Who am I missing?
Company | Ticker | Price | RevEst | Q1Rev | Price | 2011 | P/S | PE | PEG | SE |
May’11 | $M Yr. | 2011 | Apr’12 | Rev | BV | |||||
GenProbe | GPRO | 80 | 642 | 143 | 66 | 576 | 5 | 64 | 1.9 | 700 |
Abaxis | ABAX | 28 | 176 | 37.5 | 28.13 | 155 | 3.9 | 54 | 3.2 | 153 |
Alere | ALR | 2,700 | 24 | 2386 | 1.2 | n/a | 0.8 | 2,229 | ||
Cepheid | CPHD | 30.5 | 341 | 60.2 | 40.4 | 70.2 | 9.4 | 1000 | 176 | 212 |
ExactSci | EXAS | 4.12 | 10.43 | 4 | 147 | n/a | n/a | 84 | ||
GenomHlth | GHDX | 25.85 | 236 | 49.8 | 30.16 | 206 | 4.4 | 116 | n/a | 115 |
Immucor* | BLUD | 20.3 | 345 | 83.3 | 27 | n/a | 5.5 | 21.2 | 2.2 | n/a |
Luminex | LMNX | 20 | 210.3 | 43.3 | 24 | 184 | 5.4 | 70 | 1.3 | 251 |
Meridian | VIVO | 23.4 | 181 | 41 | 18.83 | 160 | 4.8 | 28 | 1.3 | 138 |
Neogen | NEOG | 40.6 | 206 | 42.2 | 38.6 | 173 | 5.2 | 41 | 2 | 210 |
Orasure | OSUR | 100 | 11.23 | 82 | 6.6 | n/a | n/a | 100 | ||
Qiagen | QGEN | 20 | 1,240 | 264 | 15.6 | 1170 | 3.1 | 38.8 | 1.7 | 2,548 |
Quidel | QDEL | 14.55 | 157.4 | 59.6 | 18.5 | 158 | 3.8 | 94 | 3.3 | 185 |
Sequenom | SQNM | 82.6 | 3.87 | 55.9 | 7.9 | n/a | n/a | 91.4 | ||
SeraCare# | SRLS | 3.7 | 46.2 | 11 | 4 | 43.5 | 1.8 | 36.3 | n/a | 40.3 |
Techne | TECH | 80.5 | 315 | 76.3 | 69 | 290 | 8.8 | 22.7 | 2 | 598 |
* sold for $1.97B to TBG Capital | #sold for $80M | |||||||||